Home » USA Broker Ratings » DexCom, Inc. – Consenus Indicates Potential 13.7% Upside

DexCom, Inc. – Consenus Indicates Potential 13.7% Upside

DexCom, Inc. with ticker code (DXCM) now have 15 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 200 and 125 with a mean TP of 178.13. Now with the previous closing price of 156.67 this would indicate that there is a potential upside of 13.7%. The day 50 moving average is 154.39 and the 200 day moving average is 142.47. The company has a market cap of $14,309m. Visit the company website at: http://www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn